Keros Therapeutics, Inc. (KROS)
USD 17.13
(-4.83%)
USD 17.13
(-4.83%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 151 Thousand | - | 20.1 Million | - | 10 Million | 10 Million |
| Cost of Revenue | 815 Thousand | 1.61 Million | 898 Thousand | 605 Thousand | 17.34 Million | 10.11 Million |
| Gross Profit | -664 Thousand | -1.61 Million | 19.2 Million | -605 Thousand | -7.34 Million | -111 Thousand |
| Operating Expenses | 169.27 Million | 107.7 Million | 76.47 Million | 44.19 Million | 20 Million | 11.32 Million |
| Selling, General and Administrative Expenses | 34.83 Million | 27.52 Million | 21.33 Million | 12.79 Million | 3.18 Million | 1.58 Million |
| Research and Development Expenses | 135.25 Million | 87.26 Million | 55.14 Million | 33.86 Million | 17.37 Million | 10.11 Million |
| Other Expenses | - | -7.08 Million | -356 Thousand | -2.46 Million | -558 Thousand | 237 Thousand |
| Cost and Expenses | 170.09 Million | 107.7 Million | 76.47 Million | 44.19 Million | 20 Million | 11.32 Million |
| Operating Income | -169.94 Million | -114.79 Million | -56.37 Million | -46.65 Million | -10.56 Million | -1.69 Million |
| Interest Expense | - | 1000.00 | 4000.00 | 6000.00 | 8000.00 | - |
| Income Tax Expense | - | 1000.00 | 2.01 Million | -172 Thousand | 8000.00 | 257 Thousand |
| Earnings before Tax | -152.99 Million | -104.67 Million | -56.73 Million | -45.53 Million | -12.33 Million | -1.07 Million |
| Net Income | -152.99 Million | -104.68 Million | -58.74 Million | -45.36 Million | -12.34 Million | -1.33 Million |
| Earnings Per Share Basic | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Earnings Per Share Diluted | -5.20 | -4.15 | -2.52 | -2.93 | -1.39 | -0.15 |
| Weighted Average Shares Outstanding | 29.44 Million | 25.24 Million | 23.33 Million | 15.5 Million | 8.88 Million | 8.88 Million |
| Weighted Average Shares Outstanding (Diluted) | 29.44 Million | 25.24 Million | 23.33 Million | 15.5 Million | 8.88 Million | 8.88 Million |
| Gross Margin | -4.40 | - | 0.96 | - | -0.73 | -0.01 |
| EBIT Margin | -1007.79 | - | -2.82 | - | -0.98 | -0.12 |
| Profit Margin | -1013.19 | - | -2.92 | - | -1.23 | -0.13 |
| EBITDA | -152.17 Million | -103.06 Million | -56.37 Million | -44.92 Million | -11.89 Million | -774 Thousand |
| Earnings Before Tax Margin | -1125.44 | - | -2.80 | - | -1.06 | -0.17 |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Revenue | 37 Thousand | 83 Thousand | 151 Thousand | 143 Thousand | 8000.00 | - |
| Cost of Revenue | 306 Thousand | 277 Thousand | 815 Thousand | 247 Thousand | 551 Thousand | 545 Thousand |
| Gross Profit | -269 Thousand | -194 Thousand | -664 Thousand | -104 Thousand | -543 Thousand | -545 Thousand |
| Operating Expenses | 50.17 Million | 48.56 Million | 167.69 Million | 44.19 Million | 43.28 Million | 41.33 Million |
| Selling, General and Administrative Expenses | 9.65 Million | 10.3 Million | - | 9.1 Million | 9.14 Million | 8.8 Million |
| Research and Development Expenses | 40.51 Million | 38.25 Million | - | 37.49 Million | 34.14 Million | 32.53 Million |
| Other Expenses | -196 Thousand | -437 Thousand | -206 Thousand | -10.94 Million | 3.84 Million | 3.83 Million |
| Cost and Expenses | 50.47 Million | 48.56 Million | 167.69 Million | 44.19 Million | 43.28 Million | 41.33 Million |
| Operating Income | -50.43 Million | -48.48 Million | -169.94 Million | -46.45 Million | -43.28 Million | -41.33 Million |
| Interest Expense | - | - | - | - | - | - |
| Income Tax Expense | - | -277 Thousand | -206 Thousand | 3.81 Million | -210 Thousand | 3.83 Million |
| Earnings before Tax | -45.25 Million | -43.11 Million | -152.99 Million | -40.24 Million | -39.44 Million | -37.5 Million |
| Net Income | -45.25 Million | -43.11 Million | -152.99 Million | -40.24 Million | -39.44 Million | -37.5 Million |
| Earnings Per Share Basic | -1.25 | -1.46 | - | -1.34 | -1.33 | -1.27 |
| Earnings Per Share Diluted | -1.25 | -1.46 | - | -1.34 | -1.33 | -1.27 |
| Weighted Average Shares Outstanding | 36.1 Million | 29.44 Million | 29.44 Million | 30.12 Million | 29.66 Million | 29.6 Million |
| Weighted Average Shares Outstanding (Diluted) | 36.1 Million | 29.44 Million | 29.44 Million | 30.12 Million | 29.66 Million | 29.6 Million |
| Gross Margin | -7.27 | -2.34 | -4.40 | -0.73 | -67.88 | - |
| EBIT Margin | -1354.95 | -584.13 | - | -279.69 | -5410.00 | - |
| Profit Margin | -1223.16 | -519.45 | -1013.19 | -281.42 | -4930.00 | - |
| EBITDA | -50.13 Million | -48.48 Million | - | -39.99 Million | -43.28 Million | -37.31 Million |
| Earnings Before Tax Margin | -1363.22 | -584.13 | -1125.44 | -324.86 | -5410.00 | - |
RKNEF
MMTIF
KREVF
UVSE
0II3
TORNTPHARM